The Global Alpha Emitter Market Growth Accelerated By Expanding Applications In Cancer Treatment
 |
| Alpha Emitter Market |
Alpha emitters are radioactive
particles that are useful in the treatment of various cancers. They work by
emitting high-energy alpha particles that can destroy targeted cancerous cells
from within while causing minimal harm to surrounding healthy tissues. Ra-223
dichloride is one such alpha emitter approved for the treatment of
castration-resistant prostate cancer. Researchers are exploring the use of
various other alpha emitter-based radiotherapies for cancers of the liver,
brain, and bone.
The global Alpha Emitter Market
is estimated to be valued at US$ 1331 million in 2023 and is expected to
exhibit a CAGR of 16% over the forecast period 2023 to 2030, as highlighted in
a new report published by Coherent Market Insights.
Market key trends:
The expanding applications of
alpha emitters in cancer treatment is one of the key trends driving the growth
of the alpha emitter market. Based on promising results from ongoing clinical
trials, regulators are expected to approve additional alpha emitter-based
radiotherapies to treat several hard-to-treat cancers in the coming years. This
will significantly increase the adoption of alpha emitters among healthcare
facilities. Furthermore, as alpha emitters allow targeted radiation therapy
while minimizing toxicity, their demand is expected to rise as cancer cases
continue to surge worldwide. Continuous research focusing on improving the
selectivity and efficacy alpha emitter-based cancer treatments augurs well for
the long-term prospects of this market.
Segment Analysis
The global alpha emitter market
is dominated by diagnostic segment, which accounted for around 65% share of the
overall market in 2023. The diagnostic segment utilize alpha emitters like
radium 223 for bone metastases treatment and actinium 225 attached to
monoclonal antibodies (mAbs) for targeted alpha therapy for cancer treatment.
These applications have driven the growth of diagnostic segment over other
segments such as therapeutic.
Key Takeaways
The Global
Alpha Emitter Market Size is estimated to be valued at US$ 1331 million
in 2023 and is expected to exhibit a CAGR of 16% over the forecast period 2023
to 2030.
North America accounted for the
largest share of around 40% of the overall alpha emitter market in 2023. The
region leads in adoption of targeted alpha therapy for cancer treatment.
Growing research in the field is also driving the North America market. Asia
Pacific is expected to witness highest growth during the forecast period owing
to improving healthcare infrastructure and increasing healthcare spending in
emerging economies of the region.
Key players: Key players operating in the alpha emitter market are
Abbott, BD, Cardinal Health, Johnson & Johnson, Medtronic, 3M, Steris,
Teleflex. Abbott leads the market owing to strong portfolio of brachytherapy
devices and seeds offering alpha emitting isotopes like iodine-125 and
palladium-103 for radiation synovectomy. 3M is another leading player driven by
wide gamma of products including soft tissue markers enabled with alpha
emitting isotope like gold-198.
Get More Insights Here
https://www.newsstatix.com/alpha-emitter-market-size-share-growth-outlook-2023-2/
Comments
Post a Comment